157 related articles for article (PubMed ID: 19384755)
1. Potential use of biodegradable nanoparticles for the photodynamic therapy of eye diseases.
Vargas A; Delie F
Arch Soc Esp Oftalmol; 2009 Apr; 84(4):169-71, 173-5. PubMed ID: 19384755
[No Abstract] [Full Text] [Related]
2. Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin.
Pegaz B; Debefve E; Ballini JP; Konan-Kouakou YN; van den Bergh H
J Photochem Photobiol B; 2006 Dec; 85(3):216-22. PubMed ID: 16979346
[TBL] [Abstract][Full Text] [Related]
3. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos.
Vargas A; Pegaz B; Debefve E; Konan-Kouakou Y; Lange N; Ballini JP; van den Bergh H; Gurny R; Delie F
Int J Pharm; 2004 Nov; 286(1-2):131-45. PubMed ID: 15501010
[TBL] [Abstract][Full Text] [Related]
4. Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity.
Vargas A; Lange N; Arvinte T; Cerny R; Gurny R; Delie F
J Drug Target; 2009 Sep; 17(8):599-609. PubMed ID: 19591536
[TBL] [Abstract][Full Text] [Related]
5. Intensive tumor suppression by anti-angiogenic photodynamic therapy with polycation-modified liposomal photosensitizer.
Takeuchi Y; Kurohane K; Nango M; Oku N
Cell Mol Biol Lett; 2002; 7(2):301. PubMed ID: 12097971
[No Abstract] [Full Text] [Related]
6. [Photodynamic therapy in the treatment of diseases of the anterior and posterior eye segments].
Egorov EA; Prokof'eva MI; Egorov AE; Novoderezhkin VV; Botabekova TK
Vestn Oftalmol; 2003; 119(2):13-5. PubMed ID: 13677999
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of porphyrins and chlorins in biodegradable nanoparticles: the effect of dye lipophilicity on the extravasation and the photothrombic activity. A comparative study.
Pegaz B; Debefve E; Borle F; Ballini JP; van den Bergh H; Kouakou-Konan YN
J Photochem Photobiol B; 2005 Jul; 80(1):19-27. PubMed ID: 15963434
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.
Preuss A; Hackbarth S; Wacker M; Knobloch T; Langer K; Röder B
J Control Release; 2010 Nov; 148(1):e117-8. PubMed ID: 21529588
[No Abstract] [Full Text] [Related]
9. Meso-tetra (carboxyphenyl) porphyrin (TCPP) nanoparticles were internalized by SW480 cells by a clathrin-mediated endocytosis pathway to induce high photocytotoxicity.
Hu Z; Pan Y; Wang J; Chen J; Li J; Ren L
Biomed Pharmacother; 2009 Feb; 63(2):155-64. PubMed ID: 18790596
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles as vehicles for delivery of photodynamic therapy agents.
Bechet D; Couleaud P; Frochot C; Viriot ML; Guillemin F; Barberi-Heyob M
Trends Biotechnol; 2008 Nov; 26(11):612-21. PubMed ID: 18804298
[TBL] [Abstract][Full Text] [Related]
11. [PDT (photodynamic therapy) treatment of choroidal neovascularisations (CNV) associated with presumed ocular histoplasmosis syndrome (POHS)].
Ringwald A
Klin Monbl Augenheilkd; 2010 Jun; 227(6):507-9. PubMed ID: 20560102
[No Abstract] [Full Text] [Related]
12. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
13. Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.
Anderski J; Mahlert L; Mulac D; Langer K
Eur J Pharm Biopharm; 2018 Aug; 129():1-9. PubMed ID: 29778525
[TBL] [Abstract][Full Text] [Related]
14. Current clinical and preclinical photosensitizers for use in photodynamic therapy.
Detty MR; Gibson SL; Wagner SJ
J Med Chem; 2004 Jul; 47(16):3897-915. PubMed ID: 15267226
[No Abstract] [Full Text] [Related]
15. In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation properties, administration parameters and biological issues involved in PDT outcome.
Vargas A; Eid M; Fanchaouy M; Gurny R; Delie F
Eur J Pharm Biopharm; 2008 May; 69(1):43-53. PubMed ID: 18023564
[TBL] [Abstract][Full Text] [Related]
16. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors.
Gary-Bobo M; Mir Y; Rouxel C; Brevet D; Basile I; Maynadier M; Vaillant O; Mongin O; Blanchard-Desce M; Morère A; Garcia M; Durand JO; Raehm L
Angew Chem Int Ed Engl; 2011 Nov; 50(48):11425-9. PubMed ID: 21976357
[No Abstract] [Full Text] [Related]
17. Nanoparticles in photodynamic therapy: an emerging paradigm.
Chatterjee DK; Fong LS; Zhang Y
Adv Drug Deliv Rev; 2008 Dec; 60(15):1627-37. PubMed ID: 18930086
[TBL] [Abstract][Full Text] [Related]
18. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
Busch T
Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of bio-derived polyhydroxyalkanoate nanoparticles as a delivery system for hydrophobic photodynamic therapy agents.
Pramual S; Assavanig A; Bergkvist M; Batt CA; Sunintaboon P; Lirdprapamongkol K; Svasti J; Niamsiri N
J Mater Sci Mater Med; 2016 Feb; 27(2):40. PubMed ID: 26712706
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy using a novel photosensitizer, EC036, is more effective compared with ATX-S10(Na) photodynamic therapy.
Takahashi H; Nakajima S; Asano R; Nakae Y; Sakata I; Iizuka H
J Dermatol Sci; 2009 Aug; 55(2):130-2. PubMed ID: 19398306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
